Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grape King BioTPE:1707 -1.98%79 5-Year Yield-on-Cost % is 7.24 as of Aug. 01, 2026, which is 75% above its 10-year median of 4.14. GuruFocus rates TPE:1707 with a GF Score™ of 79/100 and a GF Value™ of NT$138.70 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 512 Drug Manufacturers companies, Grape King Bio ranks better than 83.2% on this metric.
Grape King Bio's yield on cost for the quarter that ended in Mar. 2026 was 7.24.
The historical rank and industry rank for Grape King Bio's 5-Year Yield-on-Cost % or its related term are showing as below:
TPE:1707'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.23 Med: 4.14 Max: 10.65
Current: 7.24
During the past 13 years, Grape King Bio's highest Yield on Cost was 10.65. The lowest was 2.23. And the median was 4.14.
TPE:1707's 5-Year Yield-on-Cost % is ranked better than 83.2% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs TPE:1707: 7.24
Grape King Bio (TPE:1707) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Grape King Bio 5-Year Yield-on-Cost % Related Terms
TPE:1707 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Grape King Bio's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Grape King Bio is calculated as
Grape King Bio (TPE:1707) has a 5-Year Yield-on-Cost % of 7.24 as of Aug. 01, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Grape King Bio and its competitors. This is 75% above median its historical median of 4.14. Over the past decade, Grape King Bio's 5-Year Yield-on-Cost % has ranged from 2.23 to 10.65. According to the industry distribution chart, Grape King Bio ranks #86 out of 512 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is Grape King Bio's 5-Year Yield-on-Cost % too high?
Grape King Bio's current 5-Year Yield-on-Cost % of 7.24 is 75% above median its 10-year median of 4.14. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 10.65. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Grape King Bio's value of 7.24 is 212.1% above this industry median. Based on the distribution chart, Grape King Bio ranks #86 out of 512 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grape King Bio has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #86 out of 512 companies for 5-Year Yield-on-Cost %. This places Grape King Bio in the top 17% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.32. Grape King Bio's value of 7.24 is 212.1% above this benchmark. Historically, Grape King Bio's own 5-Year Yield-on-Cost % has ranged from 2.23 to 10.65 over the past decade. While the company's 10-year median is 4.14 vs. the industry median of 2.32, Grape King Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current 5-Year Yield-on-Cost % of 7.24 is 212.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current 5-Year Yield-on-Cost % is 7.24, which is 75% above median its own 10-year median of 4.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$138.70, compared to a current price of NT$89.30 — trading 35.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.24, which is 75% above median its 10-year median of 4.14 and 212.1% above the Drug Manufacturers industry median of 2.32. Grape King Bio's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current 5-Year Yield-on-Cost % is 7.24 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$89.30 is trading 35.6% below its estimated GF Value™ of NT$138.70.
GuruFocus considers Grape King Bio to be Significantly Undervalued.
Key valuation signals for TPE:1707:
5-Year Yield-on-Cost %: 7.24 (75% above median its 10-year median of 4.14)
GF Value™: NT$138.70 vs. price of NT$89.30 (35.6% below fair value)
Industry Position: 212.1% above the Drug Manufacturers median (#86 of 512)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
79GF Score
Get the complete analysis for TPE:1707
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
